Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells.

Ichikawa, Takehiro; Sato, Fumiaki; Terasawa, Kazuya; Tsuchiya, Soken; Toi, Masakazu; Tsujimoto, Gozoh; Shimizu, Kazuharu

Ichikawa, Takehiro; Sato, Fumiaki; Terasawa, Kazuya; Tsuchiya, Soken; Toi, Masakazu; Tsujimoto, Gozoh; Shimizu, Kazuharu.

Affiliation

Ichikawa T; Department of Nanobio Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.

PLoS One ; 7(2): e31422, 2012.

Article in En | MEDLINE | ID: mdl-22384020

Subject(s)

Antibodies, Monoclonal, Humanized/pharmacology; Breast Neoplasms/metabolism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; MicroRNAs/biosynthesis; 3' Untranslated Regions; Antineoplastic Agents/pharmacology; Cell Cycle; Cell Line, Tumor; Female; Genes, Reporter; Humans; Receptor, ErbB-2/biosynthesis; Trastuzumab

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Gene Expression Regulation, Neoplastic / Gene Expression Profiling / MicroRNAs / Antibodies, Monoclonal, Humanized Limits: Female / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2012 Document type: Article Affiliation country: Japan Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google